Oruka Therapeutics Inc. (ORKA) Options Positioning, Max Pain & Unusual Sweeps

Per the Roarable RQD rating, ORKA carries an RQD Score of 53, letter grade D+, with the verdict "Roarable Sell — Weak Fundamentals / Trim." Across the five pillars: Fundamental Cash Engine scores 7 of 20 (ROIC -18.8%; FCF yield -1.38%), indicating weak cash generation. Whale 13F Flow scores 17 of 20, the strongest pillar, reflecting institutional accumulation and options positioning. Insider Conviction scores 5 of 20 (SEC Form 4 and Congressional PTR cluster flow), a weak reading. Macro Regime Fit scores 10 of 20 (Beta 1.13; sector sensitivity), a middling reading. Forensic Balance Sheet scores 14 of 20 (Altman Z 26; Piotroski F 4/9; Debt/Equity 0.01), which is comparatively sound.

For a prospective investor, the rating's central message is that institutional positioning is supportive while the company's own cash economics and insider signals are weak. Upside drivers cited in the source data are primarily the institutional flow and the balance-sheet strength. The principal valuation tradeoff is that the stock trades at a Forward P/E of 28 while reported EPS (TTM) is -1.59 and operating margin is -6.8%, so the current price is not supported by reported earnings. The balance sheet's low leverage reduces solvency concern but does not address the negative free cash flow.

Oruka Therapeutics Inc. is a NASDAQ-listed issuer in the Health Care sector, classified under the industry Biotechnology: In Vitro & In Vivo Diagnostic Substances, per the company profile. The source data does not describe its specific products, customers, or revenue model. Reported revenue for FY 2025 and FY 2024 is $0.0M in the SEC financials, so the source data does not show a revenue-generating business in those periods. Gross margin is recorded as 0% in the market data.

Per the SEC financials, operating and net losses widened from FY 2023 to FY 2025, and free cash flow was negative in every reported period. Per the market data, the operating margin is -6.8%, the net margin is -5.9%, and ROIC is -18.8%. Per the Roarable RQD rating, the Altman Z-Score is 26, the Piotroski F-Score is 4 of 9, and the Debt/Equity ratio is 0.01, which together describe a lowly levered balance sheet with weak fundamental quality. Reported cash declined from $61.6M (FY 2024) to $46.9M (FY 2025), and the FY 2023 debt figure of $823.6M differs sharply from the $7.5M reported for FY 2025.

Six news items are listed, all tagged to ORKA. The most recent is a Yahoo Finance Singapore report on market action, institutional positioning, and fundamental catalysts (YELLOW, MARKET WIRE). A Seeking Alpha piece titled regarding a psoriasis market and the ORKA-001 asset is flagged YELLOW. A TradingView estimates item is YELLOW. A Benzinga item headlined that the stock soared is flagged GREEN with a CATALYST impact label, the only item in the set tagged as a catalyst. A Motley Fool item discusses Wall Street upside expectations (YELLOW). A Yahoo Finance item states the stock received a lift from psoriasis trial results (YELLOW). Risk watch items include the negative earnings and cash flow reported in the SEC financials. The butterfly supply-chain graph reports no supply chain and no proprietary signals.

• What specific products or pipeline assets generate or are expected to generate revenue, given reported revenue of $0.0M?
• What is the basis for the psoriasis trial results referenced in the news, and what are their stated next steps?
• Why does reported debt decline from $823.6M (FY 2023) to $7.5M (FY 2025), and what drove the change?
• What explains the 52-week range of $25.23 to $115.52, and what drove the price movement?
• What is the company's cash runway given FY 2025 free cash flow of $-88.4M against cash of $46.9M?